Environmental

RAPT’s disclosed environmental footprint appears limited relative to industrial peers because its biotech model is less resource-intensive, but filings provide little quantified emissions data.

Compared with larger life-science peers, the company’s small operating scale likely reduces absolute energy and waste burdens, though this is not supported by detailed reporting.

No material environmental controversies are evident in the provided filings, yet the absence of robust sustainability metrics limits peer transparency and comparability.

Environmental risk is mainly indirect through laboratory operations and supply-chain inputs, which are typically less burdensome than manufacturing-heavy peers but still require compliance controls.

Social

RAPT’s social profile is shaped by clinical-trial execution and patient safety, where biotech peers face similar scrutiny and the company’s disclosures remain limited.

The company’s small scale can reduce workforce and community exposure versus larger peers, but it also concentrates dependence on specialized talent and key personnel.

No major labor or product-safety controversies are evident in the provided materials, yet sparse disclosure makes peer assessment less complete than for more mature biopharma firms.

Social risk is elevated by trial outcomes and participant protection requirements, which are material across the sector and can create reputational pressure if controls are weak.

Governance

RAPT’s governance is constrained by typical small-cap biotech dependence on capital markets, which can increase dilution sensitivity relative to better-capitalized peers.

The provided metrics show very low leverage, which supports balance-sheet discipline versus more indebted peers, but does not offset broader governance concentration risks.

Stock-based compensation appears minimal in the supplied data, suggesting less shareholder dilution pressure than many development-stage peers, though disclosure remains limited.

Governance risk remains centered on board oversight, executive alignment, and financing discipline, where smaller biotechs often trail larger peers with deeper control structures.

Overall Score

RAPT’s ESG positioning is broadly in line with small-cap biotech peers, with relatively lighter environmental exposure but only moderate disclosure depth and governance resilience.

Score Driver: Limited ESG Disclosure And Small-Cap Governance Concentration Outweigh The Company’S Comparatively Low Environmental Burden.